Preventive Cardiology & Cardiometabolic Health in Portland & Lake Oswego

Heart disease often develops quietly. A person can feel well, exercise regularly and have no obvious symptoms while cardiovascular risk and atherosclerosis have been developing for years.

At HormoneSynergy®, preventive cardiology begins by understanding what that risk actually consists of. Cholesterol matters, but cholesterol alone does not describe the entire cardiovascular picture. ApoB particle burden, lipoprotein(a), triglycerides, insulin resistance, blood pressure, visceral fat, family history, smoking, sleep, physical fitness and existing atherosclerosis can all affect how an individual result should be interpreted.

The purpose of testing is not to collect more numbers. It is to identify meaningful risk, determine whether vascular disease can already be detected and decide what can reasonably be changed.

Who We Help

Preventive cardiovascular evaluation may be useful for people with elevated LDL-C or ApoB, increased lipoprotein(a), high triglycerides, insulin resistance, hypertension, a family history of premature cardiovascular disease, increasing coronary calcium or cardiovascular findings that do not seem to fit the rest of their health profile.

We also see people who appear metabolically healthy but have unexpectedly high LDL-C or ApoB, as well as patients whose routine cholesterol panel appears relatively unremarkable despite other evidence of cardiovascular risk.

Risk also changes with time. Menopause, changing body composition, increasing visceral fat, declining insulin sensitivity, sleep apnea, weight gain and loss of physical fitness can alter the metabolic and vascular environment even when earlier testing was reassuring.

LDL-C and ApoB Tell Us Different Things

LDL-C measures the amount of cholesterol carried inside LDL particles. ApoB provides a practical estimate of the number of circulating atherogenic particles because each major atherogenic particle carries one ApoB molecule.

These particles include LDL, IDL, triglyceride-rich remnants and lipoprotein(a).

LDL-C and ApoB often move together, but not always. In insulin resistance and higher-triglyceride states, cholesterol may be distributed across a larger number of particles, producing an ApoB level that is higher than the LDL-C result might suggest.

The reverse pattern also deserves attention. Some lean, physically active and insulin-sensitive people have markedly elevated LDL-C. If ApoB is also high, favorable fasting insulin, triglycerides or body composition remain beneficial, but they do not make the ApoB exposure disappear.

The updated ACC/AHA dyslipidemia guidance places increasing emphasis on cumulative exposure to atherogenic lipoproteins, earlier assessment of cardiovascular risk and the use of ApoB and other risk-enhancing markers when they add meaningful clinical information.

For a more detailed discussion, read ApoB vs LDL-C: What Actually Matters for Cardiovascular Risk?

Triglycerides and Remnant Particles

Triglycerides provide another window into lipid and metabolic physiology. Insulin resistance can increase production of triglyceride-rich VLDL particles and change the way triglycerides and cholesterol are distributed among VLDL, LDL and HDL. The remnants left as triglyceride-rich particles are metabolized can also contribute to atherosclerosis.

For that reason, we do not interpret ApoB without considering triglycerides and metabolic health. High triglycerides may accompany insulin resistance, visceral adiposity, fatty liver disease, excess alcohol intake, dietary factors or other metabolic problems.

Low triglycerides are generally favorable, but no single favorable metabolic marker should be used to dismiss another significant cardiovascular risk factor.

Related reading: Triglyceride-to-HDL Ratio and Longevity Medicine and Remnant Cholesterol and Cardiovascular Risk.

Lipoprotein(a): Inherited Risk That May Not Appear on a Standard Lipid Panel

Lipoprotein(a), or Lp(a), is an ApoB-containing lipoprotein whose concentration is largely determined by genetics. Someone can eat well, exercise regularly, maintain a healthy weight and still have a substantially elevated level.

Because Lp(a) is relatively stable throughout life, measuring it at least once in adulthood can identify an inherited source of cardiovascular risk that might otherwise remain unknown.

An elevated result does not mean that cardiovascular disease is inevitable. It can, however, influence how carefully the rest of the risk profile is assessed and how aggressively modifiable risks are addressed, particularly when there is premature cardiovascular disease in the family or more atherosclerosis than expected for age.

Related reading: Lipoprotein(a) and Cardiovascular Risk.

Metabolic Health Is Cardiovascular Health

Insulin resistance is not simply a diabetes issue. It can affect triglycerides, remnant particles, blood pressure, visceral fat, fatty liver risk, inflammatory signaling and vascular function well before fasting glucose reaches the diabetic range.

Depending on the patient, we may look at fasting glucose, fasting insulin, hemoglobin A1c, HOMA-IR, triglycerides, visceral fat, waist distribution and body composition together rather than waiting for one laboratory value to cross a diagnostic threshold.

This context matters. A lean person with good insulin sensitivity and a person with visceral obesity, hypertension and diabetes do not have identical cardiovascular risk simply because their LDL-C happens to be the same.

At the same time, favorable metabolic health does not make markedly elevated ApoB, Lp(a), hypertension, smoking or established atherosclerosis irrelevant. The point is to integrate these findings rather than allowing one favorable or unfavorable marker to define the entire patient.

Explore Metabolic Health and Longevity Medicine.

Blood Tests Measure Risk. Imaging Looks for Disease.

Laboratory testing and cardiovascular imaging answer different questions.

ApoB, LDL-C, Lp(a), triglycerides, blood pressure, glucose regulation and inflammatory markers help describe exposure and cardiovascular risk. Imaging can help determine whether atherosclerosis can already be seen.

A normal scan does not make a major risk factor harmless. A younger person with very high ApoB may not yet have accumulated enough plaque to produce an abnormal scan. Conversely, someone whose cholesterol has improved today may already carry atherosclerosis produced during decades of earlier exposure.

At HormoneSynergy®, imaging is used when the result is likely to clarify risk or meaningfully change the clinical discussion.

Coronary Artery Calcium: Looking for Calcified Atherosclerosis

A coronary artery calcium scan, or CAC, is a noncontrast CT examination that measures calcified plaque in the coronary arteries.

For selected patients, CAC can help refine cardiovascular risk because a positive score confirms that coronary atherosclerosis is already present.

A CAC score of zero can be reassuring in the appropriate clinical setting, but the meaning should be precise: no calcified coronary plaque was detected. It does not prove that the coronary arteries contain no plaque.

Noncalcified plaque can be present before enough calcium develops to produce a positive calcium score, particularly in younger people and selected higher-risk patients.

CCTA and Cleerly® Plaque Analysis

Coronary CT angiography, or CCTA, provides a different level of anatomical information. Intravenous contrast allows the coronary arteries to be visualized and can identify calcified plaque, noncalcified plaque and areas of coronary narrowing.

Cleerly® is not a separate scan. It is an AI-assisted analysis performed on suitable CCTA images. Cleerly® can quantify total coronary plaque burden and characterize plaque composition, distribution and stenosis.

This can be useful when the clinical question extends beyond whether calcified plaque is present and requires a more detailed look at coronary atherosclerosis.

CCTA with Cleerly® analysis is not automatically the right test for every patient. Age, symptoms, kidney function, contrast allergy, prior imaging, radiation exposure, known cardiovascular disease and whether the result is likely to affect treatment all matter.

Learn more about Cleerly® CCTA Heart Plaque Testing in Portland.

Carotid Ultrasound and VasoLabs®

Coronary imaging is not the only way to evaluate atherosclerosis. Carotid ultrasound can identify plaque in the carotid arteries and measure carotid intima-media thickness, or CIMT, providing another view of vascular health.

At HormoneSynergy®, VasoLabs® carotid ultrasound may include plaque assessment and CIMT measurement as part of a broader cardiovascular evaluation. It can be useful for establishing a vascular baseline or following selected patients over time.

Carotid and coronary imaging answer different questions. One should not be treated as a substitute for the other when a specific arterial territory needs to be evaluated.

Learn more about VasoLabs® Advanced Cardiovascular Screening.

Body Composition Belongs in the Cardiovascular Conversation

Body weight alone provides limited information about cardiometabolic health. Two people at the same weight may have very different amounts of visceral fat, skeletal muscle and insulin resistance.

Visceral adiposity is strongly associated with cardiometabolic risk. Loss of muscle can also impair glucose disposal, physical function and metabolic resilience even when body weight changes very little.

DEXA and SECA body-composition testing can help identify changes in lean mass, total fat and visceral fat that are not apparent on a standard scale.

These tests do not diagnose coronary atherosclerosis. They help us understand part of the metabolic environment in which cardiovascular disease develops.

Explore DEXA Body Composition, Bone Density and Visceral Fat.

What Happens When Risk Is Identified?

The value of identifying cardiovascular risk early is having time to change future exposure before a major event occurs.

For some patients, the most important work involves nutrition, resistance training, aerobic conditioning, smoking cessation, weight reduction when appropriate, preservation of lean mass, better sleep, treatment of sleep apnea, reduction of visceral fat, improvement in insulin sensitivity or treatment of hypertension.

For others, lipid-lowering medication may also be appropriate. Depending on the clinical situation, options can include statins, ezetimibe, bempedoic acid, PCSK9-directed therapies and other evidence-based treatments.

The degree and duration of LDL-C and ApoB elevation, Lp(a), age, family history, blood pressure, metabolic health, kidney function, medication tolerance and evidence of existing atherosclerosis all influence the decision.

We do not use the same treatment threshold or the same treatment plan for every patient.

Our Approach to Cholesterol Treatment

The cholesterol conversation has become unnecessarily polarized. LDL-C and ApoB are important, but cardiovascular disease cannot be reduced to one laboratory value. At the same time, good insulin sensitivity, low triglycerides or physical fitness do not make a substantial burden of ApoB-containing particles clinically irrelevant.

A person can have excellent metabolic health and still have an important inherited lipid disorder. Another may have an apparently acceptable LDL-C while ApoB reveals a larger particle burden than expected. Someone with relatively modest cholesterol abnormalities may already have significant coronary atherosclerosis, while another person with meaningful risk factors may not yet have detectable plaque.

Our job is to determine which situation is actually present and select treatment accordingly.

Preventive Cardiology as Part of Longevity Medicine

Cardiovascular disease does not develop separately from the rest of physiology. Insulin resistance changes lipoprotein metabolism. Visceral fat influences metabolic and inflammatory signaling. Sleep apnea can affect blood pressure and vascular health. Menopause can alter lipid patterns and body composition. Muscle contributes to glucose disposal, while regular exercise affects nearly every one of these systems.

This is why preventive cardiology at HormoneSynergy® is integrated with metabolic health, body composition, sleep, exercise, nutrition and hormone evaluation when clinically appropriate.

For patients who want a comprehensive baseline across these systems, the Optimal Aging Assessment provides a structured starting point that includes advanced cardiovascular and metabolic laboratory testing, body-composition assessment, vascular screening and physician interpretation.

Why Choose HormoneSynergy®?

Dr. Kathryn Retzler has practiced integrative and longevity-focused medicine for more than 25 years and has completed two preventive cardiology fellowships through the American Academy of Anti-Aging Medicine with Mark Houston, MD.

Our cardiovascular approach reflects the same philosophy used throughout HormoneSynergy®: measure what is clinically useful, understand the physiology behind the result and use that information to make better decisions.

Advanced testing can be valuable when it answers a meaningful clinical question. The fact that a test is advanced is not, by itself, a reason to order it.

Preventive Cardiology Resources

Start With the Right Level of Cardiovascular Evaluation

Some people need a broad preventive baseline. Others have a more focused question involving elevated ApoB, Lp(a), family history, changing coronary calcium or possible coronary atherosclerosis.

If it is not clear which level of evaluation makes sense, our team can help explain the available options before testing is scheduled.

Frequently Asked Questions

What is preventive cardiology?

Preventive cardiology focuses on identifying and reducing cardiovascular risk before a heart attack, stroke or other major cardiovascular event occurs. Evaluation may include laboratory testing, blood-pressure and metabolic assessment, lifestyle review and vascular or coronary imaging when appropriate.

What is ApoB and why does it matter?

ApoB provides an estimate of the number of circulating atherogenic lipoprotein particles, including LDL, IDL, triglyceride-rich remnants and lipoprotein(a). It can identify particle burden that is not always apparent from LDL-C alone.

Can ApoB be high even if triglycerides and fasting insulin are good?

Yes. Good metabolic health is favorable, but it does not guarantee a low ApoB. Some metabolically healthy people have markedly elevated LDL-C and ApoB because of genetics, dietary response or other aspects of lipid physiology.

What is Lp(a)?

Lipoprotein(a), or Lp(a), is a largely inherited ApoB-containing lipoprotein associated with cardiovascular risk. It is not included in most routine cholesterol panels.

What is the difference between CAC and CCTA?

A CAC scan is a noncontrast CT examination that detects calcified coronary plaque. CCTA uses intravenous contrast to visualize the coronary arteries and can identify both calcified and noncalcified plaque as well as areas of coronary narrowing.

Is Cleerly® the same as a CCTA?

No. CCTA is the imaging examination. Cleerly® is an AI-assisted analysis performed on suitable CCTA images to quantify and characterize coronary plaque.

Can coronary plaque be present with a calcium score of zero?

Yes. A CAC score of zero means that no calcified coronary plaque was detected. Noncalcified plaque can still be present, particularly in younger patients and selected higher-risk individuals.

What does carotid ultrasound add?

Carotid ultrasound can identify carotid plaque and measure arterial wall thickness. It provides information about atherosclerosis in a different vascular territory and can complement laboratory risk assessment.

Does good metabolic health make high LDL-C or ApoB harmless?

No. Good insulin sensitivity, normal blood pressure, physical fitness, low visceral fat and low triglycerides are favorable. They reduce important sources of cardiovascular risk but do not eliminate the significance of prolonged exposure to markedly elevated ApoB-containing particles.

Does HormoneSynergy® automatically recommend statins for high cholesterol?

No. Treatment decisions are individualized. LDL-C and ApoB exposure, Lp(a), age, family history, blood pressure, metabolic health, smoking, existing atherosclerosis, medication tolerance and overall cardiovascular risk all contribute to the decision. Statins are one evidence-based treatment option among several lipid-lowering therapies.

How does preventive cardiology connect with longevity medicine?

Cardiovascular health is closely connected with insulin sensitivity, body composition, sleep, physical activity, nutrition, hormone transitions and other systems that influence healthspan. Preventive cardiology is therefore part of the broader HormoneSynergy® longevity medicine model rather than an isolated cholesterol program.

References

• 2026 ACC/AHA Guideline on the Management of Dyslipidemia — Circulation
• 2026 ACC/AHA Guideline on the Management of Dyslipidemia — Journal of the American College of Cardiology

Editorial Transparency

This page is educational and does not replace individualized medical evaluation. Cardiovascular testing and treatment should be selected according to medical history, symptoms, laboratory findings, family history, prior imaging, medications and overall clinical context. Advanced testing is most useful when the result is likely to clarify risk or change management.